TransMedics Group (NASDAQ:TMDX) Stock Price Target Raised at JPMorgan Chase & Co.

TransMedics Group (NASDAQ:TMDX) had its price target increased by JPMorgan Chase & Co. from $73.00 to $85.00 in a report issued on Friday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Other analysts have also recently issued reports about the company. Barclays assumed coverage on TransMedics Group in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target on the stock. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Needham & Company LLC lifted their price objective on TransMedics Group from $106.00 to $110.00 and gave the company a “buy” rating in a research note on Friday. Canaccord Genuity Group boosted their target price on TransMedics Group from $95.00 to $120.00 and gave the stock a “buy” rating in a report on Friday. Finally, TD Cowen reissued a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research note on Tuesday, September 8th. Five research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $112.20.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $88.24 on Friday. TransMedics Group has a one year low of $60.10 and a one year high of $156.00. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.53 and a quick ratio of 4.15. The company’s 50-day simple moving average is $79.61 and its 200 day simple moving average is $93.17. The firm has a market capitalization of $3.05 billion, a P/E ratio of 23.91, a PEG ratio of 1.18 and a beta of 2.14.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.21. TransMedics Group had a net margin of 19.85% and a return on equity of 13.30%. The business had revenue of $203.01 million for the quarter, compared to analysts’ expectations of $178.06 million. During the same quarter in the prior year, the company earned $0.66 earnings per share. The business’s revenue was up 41.1% compared to the same quarter last year. As a group, analysts forecast that TransMedics Group will post 1.50 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director David Weill bought 1,336 shares of the stock in a transaction on Friday, September 11th. The shares were acquired at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the purchase, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

A number of institutional investors have recently made changes to their positions in TMDX. Dimensional Fund Advisors LP boosted its position in TransMedics Group by 5.5% in the first quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company’s stock worth $51,355,000 after purchasing an additional 26,969 shares during the last quarter. Braidwell LP grew its stake in shares of TransMedics Group by 85.1% during the 2nd quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after purchasing an additional 280,324 shares during the period. Wellington Management Group LLP grew its stake in shares of TransMedics Group by 6.1% during the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock valued at $34,271,000 after purchasing an additional 29,500 shares during the period. Principal Financial Group Inc. grew its stake in shares of TransMedics Group by 19.4% during the 1st quarter. Principal Financial Group Inc. now owns 231,433 shares of the company’s stock valued at $23,007,000 after purchasing an additional 37,656 shares during the period. Finally, Congress Asset Management Co. grew its stake in shares of TransMedics Group by 11.0% during the 3rd quarter. Congress Asset Management Co. now owns 252,952 shares of the company’s stock valued at $21,109,000 after purchasing an additional 25,118 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services.

The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.